<DOC>
	<DOC>NCT01114581</DOC>
	<brief_summary>The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.</brief_summary>
	<brief_title>Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Respiratory Tract Infections</mesh_term>
	<mesh_term>Guaifenesin</mesh_term>
	<mesh_term>Phenylpropanolamine</mesh_term>
	<mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
	<criteria>Symptoms of cough, thickened mucus and chest congestion Able to produce sputum Non Smoker Pregnant Smokers Fever above 101Â°F Any chronic illness</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Acute Respiratory Infection</keyword>
	<keyword>Mucociliary</keyword>
	<keyword>Cough Clearance</keyword>
	<keyword>Guaifenesin</keyword>
</DOC>